Back

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Lipids: drug therapy Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
Discussant - Lipids: drug therapy
Presentation thumbnail
Suboptimal cardiovascular risk management in cancer survivors: analysis of statin prescription patterns following coronary calcium scoring
Doctor C. Soh (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Novel risk model for predicting incident atrial fibrillation in patients at high cardiovascular risk receiving omega-3 fatty acid: sub-analysis from the STRENGTH randomized clinical trial
Doctor T. Wang (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Pleiotropic effects of inclisiran on arterial structural and functional parameters
Doctor M. Bellomare (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Lipids: drug therapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors
thumbnail
Congress Session
Registries, observational, and other studies on lipids
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on lipid therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources